Caroline Palomeque
Stock Analyst at Maxim Group
(1.30)
# 3,642
Out of 5,036 analysts
10
Total ratings
44.44%
Success rate
-0.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $2.13 | +275.59% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $26.16 | +125.54% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $190.78 | -19.28% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $66.88 | -13.28% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $200.59 | -17.24% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $16.96 | +129.95% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $13.09 | +366.00% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $9.35 | +327.81% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $2.13
Upside: +275.59%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $26.16
Upside: +125.54%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $190.78
Upside: -19.28%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $66.88
Upside: -13.28%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $200.59
Upside: -17.24%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $16.96
Upside: +129.95%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $13.09
Upside: +366.00%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $9.35
Upside: +327.81%